Experts Report the Latest Updates in Pulmonary Disease
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
The SENSCIS Trial: Exciting News for Scleroderma-Associated ILD
New Research on Therapies for Patients with Pulmonary Fibrosis
Spring 2019 — What are the Most Exciting Things Happening in Pulmonary Disease?
New Tools to Improve the Diagnosis of IPF vs Other ILDs
Biomarkers in IPF and Other ILDs
Connective Tissue Disease-Related ILD is Now in the Limelight
Patient-Centered Outcomes for Patients with IPF: Activity Monitoring
The Impact of Anticoagulation Use on IPF Patient Outcomes: A Warning About Warfarin
Which Patients with IPF Should be on Antifibrotics? The Value of Shared Decision Making
Dyspnea Assessment in Patients with IPF
Advanced Care Planning and Palliative Care Models for Patients with IPF
